What is the latest update in the AI in drug discovery market?

The AI in drug discovery market had one of its busiest quarters ever in Q1 2026, with billions of dollars flowing into new partnerships, fundraisings, and even an IPO.

This blog post covers the most important updates from January 1, 2026 to March 31, 2026, and we constantly update it as new information becomes available.

And if you want to better understand this new industry, you can download our pitch covering the AI in drug discovery market.

Summary table of the most important updates in the AI in drug discovery market

We define the AI in drug discovery market as revenue from AI-enabled software and related services that materially support the identification and design of therapeutic candidates before human trials.

We include AI used for target identification/validation, hit/lead generation, lead optimization, de novo design, repurposing, and preclinical prediction/assessment (e.g., ADMET/tox).

We exclude AI primarily used for clinical trial operations, regulatory submissions, manufacturing, pharmacovigilance, or commercial/enterprise analytics not directly tied to discovery and preclinical candidate selection.

You can also get all the latest market news for the month here.

News	Category	Date	Source
Lilly and NVIDIA committed $1 billion over five years to build a joint AI drug discovery lab	Partnership	Jan 12, 2026	NVIDIA
Generate Biomedicines raised $400 million in its IPO, pricing 25 million shares at $16	IPO	Feb 26, 2026	Generate Biomedicines
Takeda signed a deal with Iambic worth over $1.7 billion for AI-driven small-molecule design	Partnership	Feb 9, 2026	Iambic
Insilico and Lilly entered a $2.75 billion research and licensing collaboration for AI drug discovery	Partnership	Mar 29, 2026	PR Newswire
Earendil Labs announced $787 million in financing for AI-driven biologics discovery	Fundraising	Mar 20, 2026	PR Newswire
Insilico landed an $888 million oncology collaboration with Servier	Partnership	Jan 4, 2026	PR Newswire
Proxima raised an $80 million seed round led by DCVC for proximity-based AI drug discovery	Fundraising	Jan 13, 2026	Business Wire
IQVIA agreed to acquire Charles River's drug discovery assets, including a small-molecule AI platform	M&A	Feb 25, 2026	IQVIA
Isomorphic Labs started a multi-target research collaboration with Johnson & Johnson	Partnership	Jan 20, 2026	Isomorphic Labs
GSK licensed Noetik's AI foundation models in a $50 million anchor partnership for cancer research	Partnership	Jan 8, 2026	Business Wire
Isomorphic Labs said its Drug Design Engine more than doubles AlphaFold 3 accuracy on key tasks	Breakthrough	Feb 10, 2026	Isomorphic Labs
Recursion reported clinical validation of its AI stack and $754 million in cash runway into 2028	Financial results	Feb 25, 2026	Recursion

How is the AI in drug discovery market doing now?

How do we define the AI in drug discovery market?

We define the AI in drug discovery market as revenue from AI-enabled software and related services that materially support the identification and design of therapeutic candidates before human trials.

We include AI used for target identification/validation, hit/lead generation, lead optimization, de novo design, repurposing, and preclinical prediction/assessment (e.g., ADMET/tox).

We exclude AI primarily used for clinical trial operations, regulatory submissions, manufacturing, pharmacovigilance, or commercial/enterprise analytics not directly tied to discovery and preclinical candidate selection.

This is also the definition we use in our report covering the AI in drug discovery market.

How big is the AI in drug discovery market in 2026?

We estimate the AI in drug discovery market at approximately $2.9 billion in 2026, based on both third-party research and our own bottom-up calculations.

This is not a random guess, if you want to know how we have come up with this estimate, you can read our AI in drug discovery market size analysis here.

To put that in perspective, the AI in drug discovery market is roughly half the size of the $6.19 billion global preclinical CRO market and about 1.5% of the $194 billion pharma R&D spend.

The AI in drug discovery market is still early-stage (maturity score of 35/100), highly competitive (80/100), and quite fragmented (75/100), meaning lots of niche players coexist and no single vendor dominates yet.

How fast will the AI in drug discovery market grow in the future?

Under realistic assumptions, the AI in drug discovery market should grow at around 14% to 22% per year, depending on how fast pharma companies move from pilot programs to full production use of AI tools.

By 2030, the AI in drug discovery market should reach roughly $4.9 billion to $6.4 billion, and by 2036 it could be anywhere from $6.1 billion to $21.1 billion depending on the scenario.

That growth rate is much faster than traditional pharma services markets but slower than pure software markets, which makes sense because drug discovery sits at the intersection of cutting-edge AI and heavily regulated biology.

What does current funding activity look like in the AI in drug discovery market?

Our team, who continually updates our AI in drug discovery market pitch deck, is keeping a close eye on the market and tracking key signals.

One of those signals is fundraising activity across startups. Each month, we refresh this page with a list of startups of the AI in drug discovery market that have raised funding, and we also publish a quarterly analysis here.

Is funding momentum accelerating or cooling in the AI in drug discovery market these days?

Q1 2026 saw several very large fundraising rounds in the AI in drug discovery market, including Earendil Labs' $787 million financing, Proxima's $80 million seed, and Turbine's $25 million Series B, suggesting that investor appetite for AI-native drug discovery platforms remains strong.

Compared to the same period a year ago, the average deal size in Q1 2026 appears significantly larger, driven by mega-rounds like Earendil's financing that reflect growing investor confidence in scaled AI biologics and chemistry platforms.

The mix of deal sizes in Q1 2026 is notable: the AI in drug discovery market attracted both very large rounds (Earendil at $787 million) and unusually big seed rounds (Proxima at $80 million), showing that capital is flowing to both established platforms and ambitious newcomers.

Which categories and business models are attracting capital in the AI in drug discovery market?

These categories and business models of the AI in drug discovery market are receiving important fundraising currently:

• AI-driven biologics discovery attracted the largest single round, with Earendil Labs raising $787 million to scale its antibody discovery platform and internal pipeline.
• Proximity-based and novel-mechanism platforms drew investor interest, with Proxima raising $80 million in an oversubscribed seed round for AI-powered proximity medicines.
• Virtual biology and simulation platforms also attracted capital, with Turbine closing a $25 million Series B alongside a new top-10 pharma immunology deal.

The pattern is clear: investors in the AI in drug discovery market are backing companies that combine platform technology with real pharma partnerships, not just models on paper.

Who's writing the most checks in the AI in drug discovery market?

These investors are being very active when it comes to fundraising in the AI in drug discovery market:

• DCVC led Proxima's $80 million seed round, continuing its track record of backing ambitious deep-tech platforms in drug discovery and life sciences.
• Large pharmaceutical companies like Lilly, Takeda, Servier, GSK, and Johnson & Johnson are acting as both partners and funders, committing billions in deal value that effectively functions as non-dilutive capital for AI drug discovery startups.
• NVIDIA is playing a unique dual role as both an infrastructure provider and a co-investor, backing the $1 billion Lilly AI lab that brings GPU-scale compute directly into drug discovery workflows.

The investor mix in Q1 2026 shows that the AI in drug discovery market is now attracting capital from venture firms, pharma giants, and tech companies all at once.

Any big acquisitions or IPOs in the last three months in the AI in drug discovery market?

These are the big acquisitions and IPOs that happened recently in the AI in drug discovery market:

• Generate Biomedicines priced its IPO at $16 per share, raising $400 million and becoming one of the first AI-native drug discovery companies to go public in this cycle.
• IQVIA agreed to acquire drug discovery assets from Charles River Laboratories, including a small-molecule AI platform built on over 20 years of curated data.

Both moves show that AI drug discovery capabilities are now seen as strategic assets worth buying or listing, not just interesting R&D experiments.

How are companies in the AI in drug discovery market performing overall?

We are watching this market everyday, because we need to constantly update our pitch deck. Here is a couple of things we have noticed.

Are there any standout success metrics or financial results in the AI in drug discovery market?

Yes, several companies in the AI in drug discovery market reported strong results in Q1 2026:

• Recursion reported the first clinical validation of its full-stack AI system in FAP, collected $134 million in cumulative Sanofi milestones, and said it has $754 million in cash with runway into early 2028.
• Schrödinger posted $199.5 million in software revenue for 2025 and announced the upcoming commercial launch of its predictive toxicology solution in 2026.
• Absci reported successful dosing of the first three cohorts in its ABS-201 trial with favorable emerging safety data and cash runway into the first half of 2028.
• Insilico Medicine received a $5 million milestone payment from Menarini after an AI-designed cancer drug reached first-in-patient dosing in a Phase 1 study.

The common thread is that AI in drug discovery market leaders are now showing real clinical progress and milestone payments, not just impressive model outputs.

Have there been any major partnerships in the AI in drug discovery market?

Q1 2026 was one of the most active quarters ever for partnerships in the AI in drug discovery market. Here are the biggest ones:

• Lilly and NVIDIA announced a co-innovation AI lab backed by more than $1 billion over five years, connecting wet lab work with AI systems in a continuous learning loop.
• Insilico and Lilly entered a research and licensing collaboration worth up to $2.75 billion, including $115 million upfront, making it one of the quarter's largest AI drug discovery deals.
• Takeda and Iambic signed a multi-year collaboration in oncology and GI/inflammation worth over $1.7 billion in potential payments for AI-driven small-molecule design.
• Insilico announced an $888 million oncology collaboration with Servier, combining Insilico's Pharma.AI platform with Servier's oncology development capabilities.
• Isomorphic Labs started a multi-target research collaboration with Johnson & Johnson covering small molecules, antibodies, peptides, and molecular glues.
• GSK licensed Noetik's AI foundation models in a $50 million anchor deal for cancer therapeutic research.
• Merck and Mayo Clinic announced a collaboration combining Mayo's clinical and genomic data with Merck's AI capabilities for early drug discovery.
• Earendil Labs teamed with WuXi XDC to push AI-discovered antibodies toward antibody-drug conjugate development.
• Helsinn partnered with InVirtuoLabs to discover novel small-molecule therapeutics using generative AI, showing that mid-sized pharma is also adopting AI drug discovery tools.

The sheer volume and size of these partnerships show that big pharma is no longer testing AI drug discovery on the side; these companies are writing billion-dollar checks.

Have there been any notable technology or infrastructure breakthroughs in the AI in drug discovery market?

Yes, one major breakthrough stood out in Q1 2026:

• Isomorphic Labs unveiled its Drug Design Engine, which the company said more than doubles AlphaFold 3 accuracy on a challenging protein-ligand benchmark and can predict binding affinity faster and cheaper than gold-standard physics-based methods.

If these claims hold up in practice, the Isomorphic Drug Design Engine could push the AI in drug discovery market from "describing biology" toward actually designing better drugs.

Have any companies restructured or shifted pricing or business model in the AI in drug discovery market?

We did not identify any major restructurings or business model shifts during Q1 2026 in the AI in drug discovery market.

Are there any other notable wins or successes in the AI in drug discovery market?

A few more wins stood out in Q1 2026:

• Insilico Medicine launched PandaClaw, a new feature inside PandaOmics that uses AI agents to automate complex discovery workflows, making the platform more accessible to biologists who are not AI specialists.
• Generate Biomedicines hired Aarif Khakoo as Chief Scientific Officer just before its IPO, adding a key scientific leader to scale the platform across more drug programs.

Both moves reflect a broader trend in the AI in drug discovery market: companies are now focused on scaling execution and usability, not just building smarter models.

What is the overall sentiment in the AI in drug discovery market right now?

Are there any notable recent opinion pieces, thought leadership about the AI in drug discovery market?

We did not find any standalone opinion pieces or thought leadership essays worth highlighting from Q1 2026 in the AI in drug discovery market, though many of the partnership and earnings announcements above contain strong forward-looking statements about where the market is headed.

Are there any interesting and recent market research reports about the AI in drug discovery market?

There were no major new market research reports published during Q1 2026 specifically about the AI in drug discovery market, though existing estimates from firms like Grand View Research and MarketsandMarkets continue to be widely cited.

Have there been any regulatory changes, policy updates, or new compliance requirements in the AI in drug discovery market?

Our data shows that there were no significant regulatory changes, policy updates, or new compliance requirements during Q1 2026 in the AI in drug discovery market.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.